Memorial Sloan Kettering spin-out Paige will partner with Quest Diagnostics to develop precise AI-driven cancer assessment tools to speed up and improve diagnosis for patients with a range of solid tumors.
A new study finds that nearly a year after recovering from COVID-19, the body’s bone marrow plasma cells still make active antibodies against the virus. The findings appear to suggest that antibody production does not wane over time to the point of offering no protection.
The researchers used structural biology to map, at atomic scale, how certain classes of neutralizing antibodies bind to the original pandemic strain of SARS-CoV-2, the virus that causes COVID-19.
The progress was made in the study of a gene responsible for an inner-ear protein, otoferlin. Mutations in otoferlin are linked to severe congenital hearing loss, a common type of deafness in which patients can hear almost nothing.
The VITAL Act would update federal lab standards under the Clinical Laboratory Improvement Amendments (CLIA), overseen by the U.S. Department of Health and Human Services (HHS)—through which LDTs would also be regulated under the Public Health Services Act, which gives HHS authority to respond to public health emergencies.
Memo Therapeutics' candidate antibody shows good efficacy against SARS-CoV-2, including the U.K. variant. Using its technology, a new treatment can be developed within 3 weeks and the company aims to target all developing variant strains as part of an ongoing international collaboration.
The cell-attacks-host problem found in prior mouse models is due to so-called “naïve” CD4 cells. When the researchers excluded naïve CD4 cells and instead used only “memory” CD4 cells, the cells survived indefinitely in the mice without causing major damage to their hosts.
High quality microscopy has captured mammalian translation of SARS-CoV-2 viral RNA in unprecedented detail. The virus uses a ‘pseudoknot’ structure to create tension in the ribosome and promote frameshifting to translate viral RNA.
Australian researchers demonstrate that widening the fight against prostate cancer to include cancer-associated fibroblasts—cells that create fibrotic fortresses around pancreatic cancer tumors—may be an effective strategy against the disease.
Forty-eight of 50 children who were provided a gene therapy for the immunodeficiency disease ADA-SCID retain replenished immune system function two to three years after receiving their treatment.